Investigations
Query
Created At
Project
GLA - German Lymphoma Alliance18
SepNet - German Competence Network Sepsis4
Onto-Med Research Group2
FAIR4Health2
Methodical Use Case PheP2
LHA - Leipzig Health Atlas1
LIFE Adult1
LIFE HNC - Head and Neck Cancer Group1
Genetical Statistics and Systems Biology1
LIFE Heart1
MMML Demonstrators - Molecular Mechanisms in Malignant Lymphomas - Demonstrators of Personalized Medicine1
SMITH - Smart Medical Information Technology for Healthcare1
Task Force COVID-19 Leipzig1
POLAR - Polypharmacy, Drug Interactions, Risks1
Clinical Trials Leipzig1
NFDI4Health - TA3 Services1
More...
Programme
NHL18
LIFE Management Cluster6
MII - Medical Informatics Initiative4
NFDI - German National Research Data Infrastructure3
Science with and for Society (SwafS) in Horizon 20202
i:DSem - Integrative Datensemantik in der Systemmedizin1
Creator
Marita Ziepert19
René Hänsel4
Frank A. Meineke4
Christoph Beger2
Christoph Engel2
Matthias Löbe2
Alexandr Uciteli2
Markus Löffler1
Markus Scholz1
Maciej Rosolowski1
Heinrich Herre1
Toralf Kirsten1
Andreas Kühnapfel1
Sebastian Stäubert1
Alfred Winter1
Marcus Wagner1
Janne Pott1
Katrin Horn1
Udo Hahn1
Christina Lohr1
Holger Kirsten1
Torsten Thalheim1
Mona Perbix1
Franz Matthies1
More...
35
Investigations visible to you, out of a total of 41
RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Submitter: René Hänsel
Studies: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
No description specified
Submitter: René Hänsel
Studies: RICOVER-noRTh
Resources: RICOVER-noRTh metadata, RICOVER-noRTh trial data
